view original post

Zacks Investment Research cut shares of Affimed (NASDAQ:AFMD) from a hold rating to a sell rating in a research note issued to investors on Tuesday, Zacks.com reports.

According to Zacks, “Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company’s product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V., is based in Heidelberg, Germany. “

Other equities research analysts have also issued research reports about the stock. Berenberg Bank started coverage on shares of Affimed in a report on Wednesday, November 17th. They issued a buy rating for the company. Truist started coverage on shares of Affimed in a report on Thursday, October 21st. They issued a buy rating and a $10.00 target price for the company. SVB Leerink restated a buy rating on shares of Affimed in a report on Sunday, December 12th. Stifel Nicolaus initiated coverage on shares of Affimed in a report on Wednesday, September 29th. They issued a buy rating and a $12.00 target price for the company. Finally, Truist Securities initiated coverage on shares of Affimed in a report on Thursday, October 21st. They set a buy rating and a $10.00 price objective for the company. One investment analyst has rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Affimed has an average rating of Buy and a consensus target price of $12.13.

AFMD opened at $4.72 on Tuesday. Affimed has a fifty-two week low of $4.53 and a fifty-two week high of $11.74. The stock has a market capitalization of $463.91 million, a price-to-earnings ratio of -8.58 and a beta of 2.52. The company has a fifty day moving average of $6.05 and a 200 day moving average of $6.37. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.06 and a current ratio of 3.07.

Affimed (NASDAQ:AFMD) last issued its quarterly earnings data on Wednesday, November 10th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). Affimed had a negative return on equity of 40.23% and a negative net margin of 132.18%. The business had revenue of $10.21 million during the quarter, compared to analysts’ expectations of $11.79 million. During the same period in the previous year, the business earned ($0.08) earnings per share. On average, equities research analysts forecast that Affimed will post -0.53 earnings per share for the current year.

Several institutional investors have recently modified their holdings of AFMD. Goldman Sachs Group Inc. grew its position in shares of Affimed by 47.5% in the 3rd quarter. Goldman Sachs Group Inc. now owns 2,846,200 shares of the biopharmaceutical company’s stock worth $17,590,000 after buying an additional 916,189 shares during the last quarter. Point72 Asset Management L.P. grew its position in Affimed by 14.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 6,122,651 shares of the biopharmaceutical company’s stock worth $37,838,000 after purchasing an additional 786,748 shares during the last quarter. Janus Henderson Group PLC grew its position in Affimed by 126.4% during the 3rd quarter. Janus Henderson Group PLC now owns 1,192,364 shares of the biopharmaceutical company’s stock worth $7,375,000 after purchasing an additional 665,656 shares during the last quarter. Altium Capital Management LP purchased a new stake in Affimed during the 3rd quarter worth approximately $4,110,000. Finally, Tekla Capital Management LLC grew its position in Affimed by 215.5% during the 2nd quarter. Tekla Capital Management LLC now owns 908,736 shares of the biopharmaceutical company’s stock worth $7,724,000 after purchasing an additional 620,717 shares during the last quarter. 73.02% of the stock is currently owned by hedge funds and other institutional investors.

About Affimed

Affimed NV engages in the discovery and development of cancer immunotherapies. It offers ROCK novel proprietary antibody platform, which delivers types of next-generation tetravalent antibody formats, including bispecific and trispecific innate cell engagers. It operates through the following geographical segments: Germany, Europe, and USA.

Further Reading: Do equity income investments outperform growth and income investments?

Get a free copy of the Zacks research report on Affimed (AFMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Want More Great Investing Ideas?